• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

Latest Research Insights on 4-(2-methoxyethoxy)pyrimidin-2-amine (CAS: 852921-87-0) in Chemical Biology and Pharmaceutical Applications

The compound 4-(2-methoxyethoxy)pyrimidin-2-amine (CAS: 852921-87-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This pyrimidine derivative has been identified as a key intermediate in the synthesis of novel kinase inhibitors, particularly those targeting oncogenic signaling pathways. Recent studies have highlighted its role in the design of selective and potent small-molecule therapeutics, with a focus on cancer and inflammatory diseases.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the efficacy of 4-(2-methoxyethoxy)pyrimidin-2-amine as a building block for the development of next-generation EGFR (Epidermal Growth Factor Receptor) inhibitors. The study revealed that modifications at the 4-position of the pyrimidine ring, including the introduction of the 2-methoxyethoxy moiety, significantly enhanced the compound's binding affinity and selectivity for mutant EGFR isoforms. This finding is particularly relevant for the treatment of non-small cell lung cancer (NSCLC), where EGFR mutations are prevalent.

Another recent investigation, published in Bioorganic & Medicinal Chemistry Letters, explored the compound's potential in modulating immune responses. The researchers synthesized a series of derivatives based on 4-(2-methoxyethoxy)pyrimidin-2-amine and evaluated their effects on T-cell activation. The results indicated that certain derivatives could selectively inhibit JAK3 (Janus Kinase 3), a critical mediator of cytokine signaling, suggesting potential applications in autoimmune disorders such as rheumatoid arthritis and psoriasis.

From a synthetic chemistry perspective, advances in the scalable production of 4-(2-methoxyethoxy)pyrimidin-2-amine have been reported in Organic Process Research & Development. The study described an optimized, cost-effective route for its synthesis, emphasizing green chemistry principles such as reduced solvent usage and improved atom economy. This development is expected to facilitate broader access to the compound for both academic and industrial research.

Ongoing preclinical studies are further investigating the pharmacokinetic and toxicological profiles of 4-(2-methoxyethoxy)pyrimidin-2-amine derivatives. Preliminary data suggest favorable oral bioavailability and manageable toxicity, positioning these compounds as promising candidates for clinical translation. Future research directions may include combination therapies with existing anticancer agents and exploration of their utility in other therapeutic areas, such as neurodegenerative diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)